Sign in to view content

It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD

David A. Eichenbaum, MD, FASRS

Video
Published 2019

Related

Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021
Intravitreal Gene Therapy for Neovascular AMD With ADVM-022: Results of the Phase 1 OPTIC Trial
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2020
Should We Ever Consider Stopping Treatment for Neovascular AMD?
Rahul N. Khurana, MD, FASRS
Updates from the Field
2020

Category: AMD-Neovascular

See more